Notícias

Gene therapy developer advances three Phase III programs toward 2028 regulatory filings.

OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.

Ocugen (NASDAQ:OCGN) said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program. Chairman, Chief Executive Officer and Co-Founder Shankar Musunuri sa

Ocugen Inc (OCGN) advances its gene therapy pipeline with key regulatory milestones and strategic partnerships, despite a wider net loss and delayed BLA submission.

Ocugen (OCGN) delivered earnings and revenue surprises of -40.00% and +6.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Illumina (ILMN) delivered earnings and revenue surprises of +6.50% and +3.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ocugen’s latest analyst update comes with no change in its price target, leaving existing expectations intact for now. With no new analyst commentary accompanying this update, investors are left to interpret the steady price target in the context of their own view on the stock. In the sections that follow, you will see how to track these kinds of updates so you can keep up with the evolving narrative around Ocugen. Stay updated as the Fair Value for Ocugen shifts by adding it to your...

Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ocugen, Inc. (NASDAQ:OCGN) is one of the 10 Best Penny Stocks to Buy Before They Explode. On May 5, 2026, Ocugen, Inc. (NASDAQ:OCGN) reported Q1 EPS of (6c), versus the consensus estimate of (5c). Revenue totaled $1.53M, versus the consensus estimate of $358,140. Chairman, CEO, and Co-Founder Dr. Shankar Musunuri said the company completed enrollment […]

Ocugen (NASDAQ:OCGN) used its first-quarter 2026 earnings call to highlight progress across its retinal gene therapy pipeline and to outline a strengthened balance sheet following a newly announced financing. Convertible notes offering and cash runway outlook Chairman, CEO, and Co-founder Dr. Shank

Ocugen (OCGN) delivered earnings and revenue surprises of -12.57% and +27.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?